Clinical Trial

A Study of Guselkumab in Participants With Crohn's Disease and Ulcerative Colitis

Study acronym: G-FORCE
Recruiting
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate how long a participant keeps taking guselkumab or continues with their treatment plan without stopping (treatment persistence) in participants with moderate to severe Crohn's disease (CD) or ulcerative colitis (UC) in real-world setting. CD and UC are inflammatory bowel diseases, a group of inflammatory conditions of the colon and small intestine.
Protocol Amendment History 1 change
critical Recruitment opened 2026-08-01
Trial Details
NCT Number NCT07606339
Lead Sponsor Janssen-Cilag Pharma GmbH
Conditions Crohn Disease, Colitis, Ulcerative
Enrollment 35 participants
Start Date 2026-06-10
Primary Completion 2029-06-15 (estimated)
Study Completion 2029-06-15 (estimated)
Updated on ClinicalTrials.gov 2026-07-31